Prospectus For Establishment of a DSCSA Governance Body

Thani Jambulingam, Ph.D., says MFN pricing, Section 232 tariffs and PBM reform will converge to shape how pharma launches and commercializes new drugs.

In this week’s Pharma Pulse, Lilly brings Zepbound and Foundayo to Hims & Hers, Swisslog Healthcare expands its Tenutō cold storage line, and FDA adds a NAION warning across the GLP-1 class.

How the midterm results stall Trump’s MFN push, and why differential pricing, compulsory licensing and transparency dominate the WHO Fair Pricing Forum.

A CMS final rule codifies Medicare drug price negotiation from 2029, adds a fixed combination drug policy and implements a small biotech price floor.

Foreign-trade zones allow pharma companies to hold imported inventory closer to U.S. demand while deferring duties and keeping market allocation open.

The rule targets PBMs, but rebate, price protection and formulary deals they strike with drugmakers will be disclosed to plan fiduciaries and open to audit.

DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years beginning on or after July 1, 2027.

In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a federal judge declines to block Lilly’s comparative Zepbound ads, and the PBM industry’s trade group turns the vertical integration debate toward drug wholesalers.